Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 38668926.
- Also identified by DOI 10.14309/ajg.0000000000002801 and PMC identifier 11365596.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
After colectomy with ileoanal pouch anastomosis (IPAA), many patients develop high bowel frequency (BF) refractory to antimotility agents, despite normal IPAA morphology. Low circulating levels of glucagon-like protein-1 (GLP-1), a modulator of gastroduodenal motility, have been reported after colectomy. Double-blind crossover study of 8 IPAA patients with refractory high BF treated with daily administration of the GLP-1 receptor agonist liraglutide or placebo. Liraglutide, but not placebo, reduced daily BF by more than 35% ( P < 0.03). Larger randomized controlled studies are warranted to delineate the treatment potential of GLP-1 receptor agonists in IPAA patients suffering from noninflammatory high BF.
Medical subject headings
- Colonic Pouches
- Cross-Over Studies
- Liraglutide
- Proctocolectomy, Restorative